Advertisement
Advertisement
IPHA
Innate Pharma S.A. ADS
1.41
USDSponsored
+0.04
+2.92%
May 08, 15:51 UTC -4
Closed
After-Market
1.43
+0.02
+1.06%
IPHA Earnings Reports
Positive Surprise Ratio
IPHA beat 0 of 2 last estimates.
0%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q1 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Innate Pharma S.A. ADS earnings per share and revenue
On Apr 01, 2026, IPHA reported earnings of -0.55 USD per share (EPS) for Q1 26, missing the estimate of -0.16 USD, resulting in a -240.35% surprise. Revenue reached 2.79 million, compared to an expected 2.34 million, with a 19.07% difference. The market reacted with a +5.47% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
May 08, 2026 For Q1 26
Estimate
$1.33
Actual
$2.04
Surprise
+54.04%
Harmony Biosciences Holdings, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$0.72
Actual
$0.55
Surprise
-24.16%
CytomX Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.10
Surprise
+18.83%
Tectonic Therapeutic, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.20
Actual
-$1.34
Surprise
-11.07%
ALX Oncology Holdings Inc. Common Stock
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.17
Surprise
+24.24%
Entera Bio Ltd. Ordinary Shares
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.07
Surprise
+54.25%
argenx SE - ADR
Report Date
May 07, 2026 For Q1 26
Estimate
$5.47
Actual
$5.52
Surprise
+0.86%
Arrowhead Research Corporation
Report Date
May 07, 2026 For Q2 26
Estimate
-$1.16
Actual
-$0.93
Surprise
+20.32%
ImmunityBio, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-26.05%
Stoke Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.84
Actual
-$0.79
Surprise
+6.34%
FAQ
What were Innate Pharma S.A. ADS's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Innate Pharma S.A. ADS reported EPS of -$0.55, missing estimates by -240.35%, and revenue of $2.79M, 19.07% above expectations.
How did the market react to Innate Pharma S.A. ADS's Q1 2026 earnings?
The stock price moved up 5.47%, changed from $1.28 before the earnings release to $1.35 the day after.
When is Innate Pharma S.A. ADS expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Innate Pharma S.A. ADS's next earnings report?
Based on --
analysts, Innate Pharma S.A. ADS is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement